MIA Medical Director, Professor Georgina Long AO, is leading the next group of clinical trials in the use of pre-surgery immunotherapy as life-saving treatment for melanoma. Results of one of these latest neoadjuvant immunotherapy clinical trials were today published in the prestigious Nature Medicine.
Researchers have reported results from an international clinical trial assessing alternative treatment options for lentigo maligna - a non-invasive condition that commonly occurs on sun-exposed areas, particularly the face.
The International Neoadjuvant Melanoma Consortium (INMC), of which MIA’s Professor Long is a founder with three colleagues from MD Anderson USA, has been awarded the 2025 Society for Immunotherapy of Cancer Collaboration Award for its work in pioneering neoadjuvant immunotherapy for melanoma.
Melanoma Institute Australia and Cancer Council Australia are conducting a review of the clinical practice guidelines for the diagnosis and management of melanoma. The second phase is now available for review, by clinicians and the community, until 29 August 2025.
The pre-surgery use of combination immunotherapy as frontline treatment for high risk melanoma is now listed on the Pharmaceutical Benefits Scheme (PBS) and subsidised for all Australian patients.
Prestigious National Health and Medical Research Council (NHMRC) grants have been awarded for two clinical trials aiming to improve the accuracy of skin cancer diagnosis in Australia.
Read more about MIA clinicians and researchers in Chicago for ASCO25 - the American Society of Clinical Oncology Annual Meeting - to share latest research and clinical trial results with international colleagues.
Three studies led by researchers at Melanoma Institute Australia (MIA) are paving the way for less surgical and drug intervention for early stage melanoma patients.
The NHMRC grant will enable MIA to lead an international clinical trial aiming to safely reduce surgery for high risk Stage III melanoma patients who have had a good response to neoadjuvant immunotherapy.
A study has been released investigating the effectiveness of a Melanoma Care Program for patients with early-stage melanoma with varying degrees of fear of cancer recurrence after treatment of their primary melanoma.
